XML 87 R69.htm IDEA: XBRL DOCUMENT v3.26.1
FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Narrative) (Details)
$ in Thousands, € in Millions
3 Months Ended
Apr. 03, 2026
USD ($)
Apr. 03, 2026
EUR (€)
Mar. 28, 2025
USD ($)
Dec. 31, 2025
USD ($)
Dec. 04, 2025
USD ($)
Fair Value Measurement Inputs and Valuation Techniques [Line Items]          
Derivative instruments net gain (loss) to be reclassified to net income during next twelve months $ 1,600        
Life Sciences Company Convertible Debt          
Fair Value Measurement Inputs and Valuation Techniques [Line Items]          
Investment in convertible debt instrument $ 13,800 € 12      
Stated interest rate (as a percent) 4.55%        
Additional investment, contingent upon operational and financial targets $ 3,000        
Chinese Venture Capital Fund          
Fair Value Measurement Inputs and Valuation Techniques [Line Items]          
Equity method investment ownership (as a percent) 8.00%        
Precision and VSi          
Fair Value Measurement Inputs and Valuation Techniques [Line Items]          
Contingent consideration liability, current $ 7,000        
Contingent consideration liability, noncurrent       $ 1,200  
Biocoat Incorporated          
Fair Value Measurement Inputs and Valuation Techniques [Line Items]          
Earnout payments (up to) 7,000       $ 7,000
Biocoat Incorporated | Maximum          
Fair Value Measurement Inputs and Valuation Techniques [Line Items]          
Earnout payments (up to) 7,000        
Foreign exchange contracts | Not Designated as Hedging Instrument          
Fair Value Measurement Inputs and Valuation Techniques [Line Items]          
National amount 79,500     $ 73,400  
Unrealized gain (loss) on cash flow hedges, pretax $ 100   $ 600